Search - tctmd.com

Displaying 21 - 40 of 149

Sort: Relevancy | Date

News Daily News

Should Guidelines Support TAVR for Low-Risk Patients? Two Views

L.A. McKeown

August 17, 2020

News Daily News

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

Caitlin E. Cox

August 27, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

Earlier Care, More Data Needed to Increase Treatment Success in Tricuspid Regurgitation

Yael L. Maxwell

August 07, 2019

News Daily News

Stricter Regulations Needed to Maximize Cuts in Sodium Intake, UK Study Suggests

Marcus A. Banks

July 22, 2019

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

News Daily News

Abciximab in ‘Short Supply’ Worldwide

Shelley Wood

April 13, 2018

News Daily News

Sex Differences Diminish With Third-Generation TAVR Device

L.A. McKeown

January 05, 2018

News Daily News

What Works, What Matters? Patient-Centered Endpoints Gain Traction in CV Clinical Trials

Caitlin E. Cox

October 13, 2017

News Daily News

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

Todd Neale

October 09, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

Todd Neale

February 08, 2017

News Daily News

TAVR: Miracle for Some, but No Improvements in Quality of Life for Others

Yael L. Maxwell

December 22, 2016

News Daily News

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Caitlin E. Cox

October 04, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Shelley Wood

September 13, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

Advertisement

Should Guidelines Support TAVR for Low-Risk Patients? Two Views

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Earlier Care, More Data Needed to Increase Treatment Success in Tricuspid Regurgitation

Stricter Regulations Needed to Maximize Cuts in Sodium Intake, UK Study Suggests

High Mortality but Durable Results With Valve-in-Valve TAVR

Abciximab in ‘Short Supply’ Worldwide

Sex Differences Diminish With Third-Generation TAVR Device

What Works, What Matters? Patient-Centered Endpoints Gain Traction in CV Clinical Trials

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

TAVR: Miracle for Some, but No Improvements in Quality of Life for Others

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content